Business brief
Mega-Mergers, $14B AI Insurance Gaps, and Record Supercar Auctions
California approves Charter's $34.5B Cox takeover, Meta and BlackRock's AI mega-project hits insurance caps, and Sandoz expands its biosimilar pipeline.
Business
Construction valuations for AI mega-campuses have outpaced commercial insurance limits — leaving debt investors to absorb catastrophic risk on $14B data centers.
BackgroundHyper-scale AI infrastructure requires multi-billion-dollar capital investments in high-density facilities. Tight insurance capacity and rising climate risks have made comprehensive property cover prohibitively expensive for mega-projects.
- Property damage coverage is capped at $450 million during operations, leaving over 95% of the $14 billion facility's physical value uninsured.
- Credit rating agency S&P noted Meta retains rights to terminate its lease if casualty delays exceed 18 months, transferring catastrophic rebuild risk to debt investors.
- Commercial insurers are refusing to underwrite full-replacement policies for mega data centers, forcing project sponsors to accept steep coverage caps or higher debt costs.
Business
Securing California approval allows Charter to surpass Comcast as America's largest internet provider — consolidating scale against expanding fiber competitors.
BackgroundCable providers are expanding network scale to counter growing competition from fiber optic builds and wireless broadband services. Combining two of the country's largest cable operators required approvals from both federal regulators and key state utility commissions.
- The California Public Utilities Commission mandated $275 million in state network upgrades and low-income service guarantees as explicit settlement conditions.
- The combined operator will serve 35.6 million broadband customers, eclipsing Comcast in total internet subscriber count.
- Charter agreed to maintain low-income internet pricing starting at $20 per month for 100 Mbps service across all merged territories.
Business
Sandoz is deploying $322M to lock down commercial rights for Chinese biosimilars — positioning itself to capture market share from upcoming brand-name patent expirations.
BackgroundBiosimilars are near-identical, lower-cost versions of complex biological drugs that lose patent protection. Generic drugmakers are rapidly licensing candidate molecules to build market share ahead of upcoming pharmaceutical patent expirations.
- Sandoz secures commercial rights outside China, while Henlius retains clinical manufacturing operations, establishing a clear split between production and global distribution.
- Initial candidates include biosimilars for cetuximab, evolocumab, and belimumab, expanding Sandoz's active pipeline to 46 assets across high-value therapeutic areas.
- The deal includes $100.5 million in near-term upfront payments scheduled for completion during 2026, providing Henlius immediate capital for ongoing research.
Business
Surpassing $40M at auction proves collectors will pay record premiums for electric supercars — validating Ferrari's ultra-luxury EV strategy.
BackgroundLegacy supercar manufacturers are transitioning toward high-performance electric powertrains to meet changing consumer preferences and tightening emissions regulations. Co-designed with Sir Jony Ive's LoveFrom studio, the 1,050-horsepower Luce serves as Ferrari's technology flagship.
- The $40 million hammer price smashed the previous new-car auction record of $26 million set by a Ferrari Daytona SP3.
- All proceeds from the auction will benefit educational initiatives supported by The Ferrari Foundation, making the purchase tax-deductible for the anonymous buyer.
- The hand-built prototype returns to Maranello for final assembly and track calibration prior to full customer deliveries scheduled for early 2027.
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
